Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05622721 · ClinicalTrials.gov registry record
REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs
A clinical trial of Dysbiosis and Clostridium Difficile, sponsored by University of Pennsylvania.
- Active
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT05622721: Active study of Dysbiosis and Clostridium Difficile, sponsored by University of Pennsylvania.
NCT05622721 is a study of Dysbiosis and Clostridium Difficile that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 200 participants, above the 99-participant average among 13 other Dysbiosis trials with a reported enrollment target (102% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05622721, a study of Dysbiosis and Clostridium Difficile, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Antimicrobial therapy can lead to disruption of the gut microbiome and infection with Clostridioides difficile, a disease associated with high morbidity and mortality, particularly among the elderly. Drawing on observations that pet ownership and close contact with pets are protective against colonization with C. difficile and recurrence of C. difficile infection, the proposed study will test the hypothesis that microbiota that provide colonization resistance against C. difficile are shared between patients and their pets and that pet contact can mitigate antimicrobial-associated gut dysbiosis and the risk of C. difficile infection. This study will further define epidemiologic and pathophysiologic characteristics of C. difficile infection and gut microbiome dysbiosis that could enhance therapeutic options for these conditions, potentially through non-invasive interventions involving animal contact.
Primary Outcome
Changes in alpha diversity, beta diversity and composition of the gut microbiome will be ascertained between baseline (prior to taking antibiotics) and 3, 10, 30 and 90 days following the start of the antibiotic regimen
Conditions Studied
Study Locations (1)
Pennsylvania
- The Robert Schattner Center, University of Pennsylvania, School of Dental Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-05-30 |
| Est. Completion | 2026-05-01 |
What the registry record for NCT05622721 still lists
NCT05622721 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 99-participant average among 13 other Dysbiosis trials with a reported enrollment target (102% higher).
The record links to 4 conditions, with Dysbiosis appearing as the primary indexed condition, and to 0 interventions.
NCT05622721 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05622721 about?
NCT05622721 is a clinical study titled "REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs". Antimicrobial therapy can lead to disruption of the gut microbiome and infection with Clostridioides difficile, a disease associated with high morbidity and mortality, particularly among the elderly. Drawing on observations that pet ownership and close contact with pets are protective against coloni...
What is the current status of trial NCT05622721?
This trial is currently active not recruiting. The enrollment target is 200 participants. The study started on 2022-05-30. Estimated completion is 2026-05-01.
What conditions does trial NCT05622721 study?
This clinical trial studies the following conditions: Dysbiosis, Clostridium Difficile, Antibiotic-Associated Colitis, Pet-Human Bonding.
Who is sponsoring clinical trial NCT05622721?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05622721 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dysbiosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05622721's enrollment target sits among peer trials
200 3rd of 13 higher than 11 of 13 other Dysbiosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dysbiosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Peanut Butter on Gut and Metabolic Health
RECRUITING · NA
-
Personalized GI Motility Responses to Diet
RECRUITING · NA
-
Effect of Lentils and Chickpeas on Gut Microbiome and Metabolic Health
RECRUITING · NA
-
A Study of Healthy Microbiome, Healthy Mind
RECRUITING · NA
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Effect of Watermelon on Gut and Cardiometabolic Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI